Across TCGA pan-cancer cohorts, MIR3142HG Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR3142HG data layer compared with 22 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MIR3142HG Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR3142HG expression acts as an unfavorable survival marker.
HNSC are the cancer types where MIR3142HG Mutation most reproducibly stratifies survival.